As the fight against the COVID-19 pandemic continues, reports indicate that the global vaccination rate is still far below the target. Understanding the levels of reinfection may help refocus and inform policymakers on vaccination. This retrospective study in Malawi included individuals and patients who tested for COVID-19 infections via reverse transcriptase polymerase chain reaction (rt-PCR) from the data at the Public Health Institute of Malawi (PHIM). We included all data in the national line list from April 2020 to March 2022. Upon review of 47,032 records, 45,486 were included with a reported 82 (0.18) reinfection representing a rate of 0.55 (95% CI: 0.44-0.68) per 100,000 person-days of follow-up. Most reinfections occurred in the first 90 to 200 days following the initial infection, and the median time to reinfection was 175 days (IQR: 150-314), with a range of 90-563 days. The risk of reinfection was highest in the immediate 3 to 6 months following the initial infection and declined substantially after that, and age demonstrated a significant association with reinfection. Estimating the burden of SARS-CoV-2 reinfections, a specific endurance of the immunity naturally gained, and the role played by risk factors in reinfections is relevant for identifying strategies to prioritise vaccination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383452PMC
http://dx.doi.org/10.3390/vaccines11071185DOI Listing

Publication Analysis

Top Keywords

initial infection
8
reinfection
6
coronavirus disease
4
disease 2019
4
2019 covid-19
4
covid-19 reinfection
4
reinfection rates
4
rates malawi
4
malawi tool
4
tool guide
4

Similar Publications

Background: Vancomycin, an antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA), is frequently included in empiric treatment for community-acquired pneumonia (CAP) despite the fact that MRSA is rarely implicated in CAP. Conducting polymerase chain reaction (PCR) testing on nasal swabs to identify the presence of MRSA colonization has been proposed as an antimicrobial stewardship intervention to reduce the use of vancomycin. Observational studies have shown reductions in vancomycin use after implementation of MRSA colonization testing, and this approach has been adopted by CAP guidelines.

View Article and Find Full Text PDF

CCL3 as a novel biomarker in the diagnosis of necrotizing enterocolitis.

BMC Pediatr

December 2024

Department of Clinical Laboratory, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, NO 136 Zhongshaner Road, Yuzhong Distrit, Chongqing, 400014, China.

Objectives: Neonatal necrotizing enterocolitis (NEC) is a common intestinal disease that threatens the lives of newborns and is characterized by ischemic necrosis of the small intestine and colon. As early diagnosis of NEC improves prognosis, the identification of new or complementary biomarkers is of great importance. In this study, we evaluate the diagnostic value of CCL3 in NEC and compare its effectiveness with other commonly used biomarkers, such as procalcitonin (PCT) and C-reactive protein (CRP).

View Article and Find Full Text PDF

Cryptococcus neoformans/gattii and Histoplasma capsulatum var. capsulatum may present atypical histopathological features inducing diagnostic errors. We aimed to estimate the frequency of these atypical features on formalin-fixed tissue samples (FT) and to assess the relevance of an integrated histomolecular diagnosis using specific Histoplasma capsulatum PCR and panfungal PCR followed by Sanger sequencing and/or targeted-massive parallel sequencing (MPS).

View Article and Find Full Text PDF

Background: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP.

Objectives: To compare the efficacy (treatment-failure and mortality) and tolerability (treatment change) of PCP treatment-regimens with a frequentist network meta-analysis (NMA).

View Article and Find Full Text PDF

Burkholderia pseudomallei, a soil-borne bacterium that causes melioidosis, endemic in South and Southeast Asia and northern Australia, is now emerging in new regions. Since the 1990s, cases have been reported in French overseas departments, including Martinique and Guadeloupe in the Caribbean, and Reunion Island and Mayotte in the Indian Ocean, suggesting a local presence of the bacterium. Our phylogenetic analysis of 111 B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!